Joyce Liu
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joyce Liu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:41 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06369155 · Azenosertib in Uterine Serous Carcinoma: Biomarker StudyJoyce Liu, MD · recruiting · Uterine Serous Carcinoma, Uterine Carcinoma, Uterine Cancer · principal investigator
- Ph2NCT04590248 · A Study of Adavosertib as Treatment for Uterine Serous CarcinomaAstraZeneca · completed · Uterine Serous Carcinoma · principal investigator
- Ph2NCT03668340 · AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine CarcinosarcomaDana-Farber Cancer Institute · active not recruiting · Uterine Cancer · principal investigator
- Ph2NCT02873962 · A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibDana-Farber Cancer Institute · active not recruiting · Peritoneal Cancer, Ovarian Cancer, Fallopian Tube Cancer · principal investigator
- Ph1NCT02661815 · A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological CancerDana-Farber Cancer Institute · terminated · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma · principal investigator
- Ph2NCT01283035 · A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal CancerNational Cancer Institute (NCI) · completed · Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- PDX Modeling CoreP01CA269021 · NCI · DANA-FARBER CANCER INST · fiscal years 2024 to 2026 · $433,259 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Administrative CoreP30CA006516 · NCI · DANA-FARBER CANCER INST · PI Deborah J Goff · fiscal years 2018 to 2026Named on NCT01283035
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:41 UTC. The ranking covers the 200 most relevant of 3577 PubMed records, and a shared surname and initials can bring in a namesake. All 3577 on PubMed
- Adjunctive Middle Meningeal Artery Embolization for Subdural Hematoma.N Engl J Med · 2024278 citationsRCR 79.8
- Middle Meningeal Artery Embolization for Nonacute Subdural Hematoma.N Engl J Med · 2024220 citationsRCR 62.0
- Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.N Engl J Med · 202689 citationsRCR 44.5
- 83 citationsRCR 27.3
- 79 citationsRCR 15.8
- Intravenous Tenecteplase before Thrombectomy in Stroke.N Engl J Med · 202564 citationsRCR 18.1
- Cardiometabolic benefits of a non-industrialized-type diet are linked to gut microbiome modulation.Cell · 202558 citationsRCR 15.6
- Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke.N Engl J Med · 202556 citationsRCR 16.3
- Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.Nat Med · 202550 citationsRCR 16.8
- 46 citationsRCR 7.3